Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Midazolam + NVL-655 + Repaglinide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Midazolam | Dormicum | Dea No. 2884 | ||
| NVL-655 | NVL655|NUV-655|NUV655|Neladalkib | ALK Inhibitor 34 | NVL-655 is a brain-penetrant inhibitor of ALK, with activity against ALK fusions and mutations, which may result in decreased cell growth and tumor regression (PMID: 39269178). | |
| Repaglinide | GlucoNorm | AG-EE 388 ZW |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05384626 | Phase Ib/II | Itraconazole + NVL-655 Midazolam + NVL-655 + Repaglinide NVL-655 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 4 |